-
1Academic Journal
Συγγραφείς: С. Г. Багрова
Πηγή: Malignant tumours; Том 12, № 3s1 (2022); 39-42 ; Злокачественные опухоли; Том 12, № 3s1 (2022); 39-42 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: деносумаб, остеомодифицирующие агенты, антирезорбтивная терапия, бисфосфонаты, золедроновая кислота
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/998/695; Багрова С. Г., Басин Е. М., Валиев А. К., Деньгина Н. В., Копп М. В., Кутукова С. И. и соавт. Профилактика и лечение патологии костной ткани при злокачественных новообразованиях. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2021 (том 11). 38.; von Moos R. Costa L. Gonzalez-Suarez E. et al. Management of bone health in solid tumours : from bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019; 76 : 57–67.; Coleman R, et al. Bone health in cancer : ESMO Clinical Practice Guidelines. Ann Oncol 2020 : S0923–7534 (20) 39995–6.; NCCN Guidelines Version 1.2022. Adult Cancer Pain / https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1413.; O’Carrigan B, Wong MH, Willson ML, et al : Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 10 : CD003474, 2017. 42; Roger von Moosa, Jean-Jacques Bodyb, Alex Riderc et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. Journal of Bone Oncology 11 (2018) 1–9.; Guy Hechmati, A. Brett Hauber et al. Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom. Supportive Care in Cancer 2323, pages21–28 (2015).; Wang X, Yang KH, Wanyan P, Tian JH : Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment : A meta-analysis of randomized controlled trials. Oncol Lett 7 : 2014.; Henry D, Vadhan-Raj S, Hirsh V, et al : Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer : An analysis of 2017 data from patients with solid tumors. Support Care Cancer 22 : 679, 2014.; Otto S., Pautke C., Van den Wyngaert T. et al. Medication-related osteonecrosis of the jaw : prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018; 69 : 177–187.; Tanda N, Tada H, Washio J, Takahashi N, Ishida T, Koseki T (2022) Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer : A retrospective cohort study. PLOS ONE %7C https://doi.org/10.1371/journal.pone.0269335/ June 3, 2022; https://www.malignanttumors.org/jour/article/view/998
-
2Academic Journal
Συγγραφείς: A. V. SNEGOVOY, I. B. KONONENKO, V. B. LARIONOVA, L. V. MANZYUK, Антон Владимирович Снеговой, Инесса Борисовна Кононенко, Вера Борисовна Ларионова, Людмила Валентиновна Манзюк
Πηγή: Malignant tumours; № 4s2 (2015); 28-34 ; Злокачественные опухоли; № 4s2 (2015); 28-34 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: остеомодифицирующие агенты, поддерживающая терапия, анемия, Г-КСФ, нейтропения, метастазы в кости
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/164/174; Практические рекомендации по клиническому применению остеомодифицирующих агентов у пациентов с метастазами злокачественных опухолей в кости, http://www.rosoncoweb.ru/standarts/RUSSCO/2–03.pdf; Практические рекомендации по лечению анемии у больных злокачественными новообразованиями http://www.rosoncoweb.ru/standarts/RUSSCO/2–01.pdf; Практические рекомендации по назначению г-ксф с целью профилактики развития фебрильной ней тропении http://www.rosoncoweb.ru/standarts/RUSSCO/2–04.pdf; Cancer- and chemotherapy-induced anemia [электронный ресурс] //NCCN Guidelines. – v2.2011 – URL: http://www.nccn.org (дата обращения 20.08.2010).; Caggiano V., Weiss R. V., Rickert T. S. et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy // Cancer. 2005. Vol. 103. P. 1916–1924.; Kuderer N. M., Dale D., Crawford J., Lyman G. H. The impact of febrile neutropenia in hospitalized cancer patients: morbidity, mortality, and cost // J. Clin. Oncol. 2004. Vol. 22. 14 S.; Shayne M., Crawford J., Dale D. et al. For the ANC Study Group: Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy // Breast. Cancer. Res. Treat. 2006. Vol. 100. P. 255–262.; Skipper H. E. Kinetics of Mammary Tumor Cell Growth and Implications for Therapy // Cancer. 1971. Vol. 28. P. 1479.; Dale D., Crawford J. et al. Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review // Proceedings Amer. Society Clin. Oncol. 2001. Vol. 20. P. 410a. Abstract.; Aapro M. S., Cameron D. A. et al. The European Organisation for Research and. EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of; chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours // Eur. J. Cancer. 2006. Vol. 42. P. 2433–2453.; Smith T. J., Khatcheressian J. et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline // J. Clin. Oncol. 2006. Vol. 24. P. 3187–3205, Vol. 28. P. 1479.; Bronchud M. H., Potter M. R., Morgenstern G. et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients // Br. J. Cancer. 1988. Vol. 58. № 1. P. 64–69. Bennett C. L., Djulbegovic B, Norris L. B., Armitage J. O. Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy // N. Engl. J. Med. Vol. 368. P. 12.; Molineux G. The design and development of pegfilgrastim (PEGrmetHuG-CSF, Neulasta) // Curr. Pharm. Des. 2004. Vol. 10. P. 1235–1244.; Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients // Anticancer. Drugs. 2003. Vol. 14. P. 259–264.; Johnston E., Crawford J., Blackwell S. et al. Randomized, doseescalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy // J. Clin. Oncol. 2000. Vol. 18. № 13. P. 2522–2528.; Stopeck AT et al. “Denosumab Compared with ZA for the treatment of bone metastases in patients with advancat breast Cancer” JCO., 29, 7101, 2010.; https://www.malignanttumors.org/jour/article/view/164; undefined
Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/164